Search the Newsreel

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5

Oppenheimer has reiterated its Buy rating on Inhibikase Therapeutics (IKT.US), maintaining a target price of $5. This indicates continued confidence from the firm in the company's prospects.

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics announced its Q2 2026 financial results, reporting a net loss of $19.6 million and $159.0 million in cash and marketable securities. The company highlighted significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, including regulatory approvals in 26 countries and recent …

Inhibikase Q2 Results: Net Loss Widens to $19.6 Million

Inhibikase Therapeutics reported a Q2 2026 net loss of $19.6 million, or $(0.11) per share, which met analyst estimates but widened from the previous year due to increased R&D spending for its Phase 3 PAH program. The company also raised $50 million through a …

Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview

Inhibikase Therapeutics, Inc. is projected to report a loss of 11 cents per share in its upcoming earnings. This article serves as an earnings preview, indicating the anticipated financial performance for the company.

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has received a consensus "Buy" recommendation from nine brokerages, with an average 12-month price target of $5.40. The company's shares recently opened at $2.47, up 2.5%, with a market capitalization of $326.11 million. Several institutional investors, including Goldman Sachs Group …

BESIKTAS FUTBOL - KAP Haberleri - 2026-08-07 tarihli

Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT

Perceptive Advisors LLC significantly reduced its stake in Inhibikase Therapeutics (NASDAQ:IKT) by selling over 3.1 million shares, though other institutional investors like Sands Capital Alternatives and ADAR1 Capital Management increased their holdings. Despite this sale, analyst sentiment remains largely positive with an average "Buy" …

Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT

This article provides a basic financial overview for Inhibikase Therapeutics, Inc. (NASDAQ:IKT) on TradingView. It indicates that the market is closed, with no current trades. The content primarily lists available financial data categories and links to various TradingView products and community features, rather than …

18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT)

RA Capital Healthcare Fund, L.P., a ten percent owner of Inhibikase Therapeutics, Inc. (IKT), executed an Exchange Agreement on July 29, 2026. The fund swapped 18,030,000 shares of common stock for a pre-funded warrant exercisable for the same number of shares at $0.001 per …

RA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants

RA Capital Management, L.P., along with RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, have disclosed a beneficial ownership of 14,653,994 shares, capped at 9.99%, in Inhibikase Therapeutics, Inc. (IKT) through stock and pre-funded warrants. The pre-funded warrants include a "Beneficial Ownership …

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status

H.C. Wainwright has reiterated a Buy rating and an $8.00 price target for Inhibikase Therapeutics Inc (NASDAQ:IKT) after the company received FDA Orphan Drug Designation for IKT-001, its lead product candidate for pulmonary arterial hypertension. This designation provides significant incentives and potential market exclusivity. …

Inhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Inhibikase Therapeutics Inc's (IKT) financial health, ranking it 237 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, but its operating efficiency is low. Key financial metrics such as …

ADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT

ADAR1 Capital Management LLC significantly reduced its stake in Inhibikase Therapeutics (NASDAQ:IKT) by 18.1% in the first quarter, selling over 1.4 million shares. Despite this reduction, other institutional investors like BNP Paribas Financial Markets, Barclays PLC, and Virtu Financial LLC increased their positions. The …

IKT|Inhibikase Therapeutics Inc|Price:2.217|Chg%:-0.093

Inhibikase Therapeutics Inc (IKT) shows strong fundamentals and high growth potential, despite recent technical trends not fully supporting its performance. The company is considered fairly valued and has high institutional ownership. Analysts have given it a "Buy" rating with a target price indicating significant …

Iktinos Hellas S.A. Revenue Breakdown – ATHEX:IKTIN

Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Inhibikase Therapeutics Inc (IKT), highlighting its current valuation score of 6.53 and its ranking within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -5.42, which is significantly below its recent high and …

IKT|Inhibikase Therapeutics Inc|Price:2.330|

This article provides an analysis of Inhibikase Therapeutics Inc (IKT), highlighting its healthy fundamentals, high growth potential, and "Buy" rating from analysts with a target price of $6.00. Despite strong stock performance and outperforming fundamentals, technical indicators suggest the stock is trading sideways, suitable …

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Inhibikase Therapeutics (Nasdaq: IKT) announced that the FDA has granted Orphan Drug Designation (ODD) to its lead product candidate IKT-001 for the treatment of Pulmonary Arterial Hypertension (PAH). This designation highlights the significant unmet medical need for the approximately 50,000 PAH patients in the …

Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of the dividend and stock split history for Inhibikase Therapeutics Inc (IKT). It notes that the company has not distributed any dividends in the past five years. The article also details multiple 6-to-1 merger-based stock splits that occurred on …

Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Sell at Wall Street Zen

Wall Street Zen has upgraded Inhibikase Therapeutics (NASDAQ:IKT) from "strong sell" to "sell." This decision comes amidst varied analyst opinions, with some maintaining "sell" ratings while others have initiated "strong-buy" or "outperform" ratings with price targets of up to $5.00. The company's stock opened …

Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans

Inhibikase Therapeutics announced that its lead product candidate, IKT-001, has received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of Pulmonary Arterial Hypertension (PAH), a condition affecting approximately 50,000 Americans. This designation provides incentives such as tax credits, exemption from FDA …

Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

This article is a preliminary proxy statement (PRE 14A) filed by Inhibikase Therapeutics. The document pertains to a merger or acquisition, indicating that the company is involved in a corporate transaction that requires shareholder approval or notification. The specific details of the merger or …

Frontier tech research, news & data

This article provides an inventory turnover analysis for Inhibikase Therapeutics, Inc. (IKT), drawing data from SEC EDGAR filings. It presents both annual and quarterly inventory turnover figures, noting that the company's inventory turnover was "—" for all listed periods, indicating a lack of activity …

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics

RA Capital Management has filed an initial beneficial ownership statement (Form 3) for Inhibikase Therapeutics, declaring indirect ownership of 25 million common shares. This filing indicates RA Capital owns 10% of Inhibikase Therapeutics. The event date for the ownership was July 10, 2026, with …

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Inhibikase Therapeutics (NASDAQ:IKT) from a "sell" to a "strong sell" rating. Despite this downgrade, other analysts maintain a more positive outlook, with a consensus "Buy" rating and an average price target of $5.40. The company, a clinical-stage biotech focused …

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase

RA Capital, through its Healthcare Fund, has reported a 15.9% stake in Inhibikase Therapeutics (IKT), holding 25 million shares. This ownership arose from an at-the-market offering on July 10, 2026, and the percentage is calculated based on an updated share count including these newly …

Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn Continues - Share Repurchase Impact

Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics (IKT) Holds Near Support Amid Modest Gains - Late Stage Breakouts

Inhibikase Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines - Slow Growth Warning

Inhibikase Therapeutics (IKT) Earnings Date and Reports 2026 $IKT

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress